Preliminary Trial of SNA014 for Pancreatic Cancer
ConditionPancreatic Cancer
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSmartNuclide Biopharma
About this trial
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Eligibility criteria
Qualifiers
Aged between 18 and 75 years (inclusive);
Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
Disqualifiers
Patients with other clearly diagnosed malignant tumours;
Patients with uncontrolled severe infections, or those with other serious comorbidities;
Patients with a life expectancy of ≤3 months;
Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
Trial design
Treatments tested in this trial
- 68Ga-NODAGA-SNA006
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
SmartNuclide Biopharma
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Source ClinicalTrials.gov